Voyager Therapeutics (NASDAQ:VYGR) announces the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie (NYSE:ABBV) thereby regaining all rights to the vectorization technology and certain novel vectorized antibodies developed under the partnership.
The tau agreement was inked in 2018 followed by the alpha-synuclein deal in 2019.
Voyager does not anticipate any changes to its cash runway guidance from AbbVie’s exit and continues to expect that its current resources will be sufficient to fund operations into mid-2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.